Asset profile
Epirubicin
Small molecule
Evidence outlook · results not reported
NCT00002529 · Breast Cancer
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT00002529: The study was randomized and included active comparator groups, with 452 participants, but it was not blinded. Overall survival was the primary clinical endpoint; however, no results are posted, so whether the primary endpoint was met or missed is unknown.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 29 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Epirubicin: this drug | Phase 3 | Small molecule | Topoisomerase II / DNA | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Exemestane | Approved | Small molecule | Aromatase | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Gedatolisib | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 | ||
| Gemcitabine | Approved | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(34 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (7)
October 2026 (1)
What to watch
December 2026 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (12)
March 2027 (2)
April 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (2)
September 2027 (1)
What to watch
December 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (7)
March 2028 (2)
June 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
October 2028 (1)
What to watch
November 2028 (1)
What to watch
2029 (2)
2030 (2)
November 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (1)
January 2031 (1)
What to watch
2033 (1)
March 2033 (1)
What to watch
2034 (1)
August 2034 (1)
What to watch
2035 (1)
September 2035 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.